Pharmacokinetics of gallium maltolate after intragastric administration in adult horses.

OBJECTIVE To determine the pharmacokinetics of gallium maltolate (GaM) after intragastric administration in adult horses. ANIMALS 6 adult horses. PROCEDURES Feed was withheld for 12 hours prior to intragastric administration of GaM (20 mg/kg). A single dose of GaM was administered to each horse via a nasogastric tube (time 0). Blood samples were collected at various time points from 0 to 120 hours. Serum was used to determine gallium concentrations by use of inductively coupled plasma-mass spectroscopy. Noncompartmental and compartmental analyses of serum gallium concentrations were performed. Pharmacokinetic models were selected on the basis of the Akaike information criterion and visual analysis of plots of residuals. RESULTS Serum concentration data for 1 horse were such that this horse was considered an outlier and excluded from noncompartmental and compartmental analyses. Noncompartmental analysis was used to determine individual pharmacokinetic parameters. A 1-compartment model with first-order input and output and lag time was selected as the best-fit model for the data and used to determine mean ± SD values for maximum observed serum concentration (0.28 ± 0.09 μg/mL), time of maximum concentration (3.09 ± 0.43 hours), time to the first measurable concentration (0.26 ± 0.11 hours), apparent elimination half-life (48.82 ± 5.63 hours), area under the time-concentration curve (20.68 ± 757 h•μg/mL), and apparent volume of distribution (73,493 ± 18,899 mL/kg). CONCLUSION AND CLINICAL RELEVANCE Further studies are necessary to determine the bioavailability of GaM after intragastric administration in adult horses.

[1]  N. Cohen,et al.  Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals. , 2010, Journal of veterinary pharmacology and therapeutics.

[2]  J. Wood,et al.  Factors associated with failure of thoroughbred horses to train and race. , 2010, Equine veterinary journal.

[3]  J. Denoix,et al.  Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. , 2010, Equine veterinary journal.

[4]  C. Kawcak,et al.  A Review of the Efficacy of Tiludronate in the Horse , 2008 .

[5]  Robert J. Taylor,et al.  Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals. , 2007, American journal of veterinary research.

[6]  M. Doucet,et al.  Pharmacological effects of tiludronate in horses after long-term immobilization. , 2007, Bone.

[7]  J. Denoix,et al.  Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. , 2007, American journal of veterinary research.

[8]  L. Bernstein 31Ga Therapeutic Gallium Compounds , 2005 .

[9]  P. Croucher,et al.  The pharmacology of bisphosphonates and new insights into their mechanisms of action , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  N. Udagawa,et al.  Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. , 1997, Bone.

[11]  J. Kaneene,et al.  The Michigan equine monitoring system. II. Frequencies and impact of selected health problems. , 1997, Preventive veterinary medicine.

[12]  A. Barbier,et al.  The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+‐ATPase , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  L. S. Stern,et al.  The effects of gallium nitrate on osteopenia induced by ovariectomy and a low-calcium diet in rats. , 1994, Bone and mineral.

[14]  R. Bockman,et al.  Gallium nitrate increases type I collagen and fibronectin mRNA and collagen protein levels in bone and fibroblast cells , 1993, Journal of cellular biochemistry.

[15]  R. Bockman,et al.  Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  J. Reginster,et al.  Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. , 1992, Bone.

[17]  P. Schlesinger,et al.  Reversible inhibition of osteoclastic activity by bone‐bound gallium (III) , 1992, Journal of cellular biochemistry.

[18]  R. Warrell,et al.  Metabolic effects of gallium nitrate administered by prolonged infusion. , 1985, Cancer treatment reports.

[19]  P D Rossdale,et al.  Epidemiological study of wastage among racehorses 1982 and 1983 , 1985, Veterinary Record.

[20]  R. Warrell,et al.  Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. , 1984, The Journal of clinical investigation.

[21]  A. Brody,et al.  Gallium nitrate (NSC‐15200) induced toxicity in the rat. A pharmacologic, histopathologic and microanalytical investigation , 1979, Cancer.

[22]  Kiyoshi Yamaoka,et al.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  B. Noll,et al.  Chemistry and Pharmacokinetics of Gallium Maltolate, a Compound With High Oral Gallium Bioavailability , 2000, Metal-based drugs.

[24]  S. Reid,et al.  Wastage in the Australian thoroughbred racing industry: a survey of Sydney trainers. , 1997, Australian veterinary journal.

[25]  E. Siris,et al.  A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. , 1995, The Journal of clinical endocrinology and metabolism.